Chong Kun Dang Bio and Yonsei Medical Center Establish Joint Microbiome Clinical Research Center

Jung Jin Lee, CEO of Chong Kun Dang Bio (left), and Jae Young Choi, Director of Industry-Academic Cooperation Group at Yonsei University Medical Center, are taking a commemorative photo after the signing ceremony for the establishment of the Microbiome Joint Clinical Research Center and the joint research and development agreement for microbiome therapeutics.

[Asia Economy Reporter Lee Gwan-joo] Chong Kun Dang Bio announced on the 20th that it has signed an agreement with Yonsei University Medical Center Industry-Academic Cooperation Foundation to establish a Microbiome Joint Clinical Research Center and to jointly research and develop microbiome therapeutics.

Through this agreement, Chong Kun Dang Bio and Yonsei Medical Center plan to open the Microbiome Joint Clinical Research Center within Severance Hospital in September and engage in research and development of microbiome therapeutics for indications with high demand for treatment development, such as inflammatory bowel disease, Alzheimer's dementia, and respiratory infectious diseases.

Chong Kun Dang Bio established the only domestic Intestinal Microbiome Bank (IMB) in 2017 and is conducting numerous national projects, researching microbiome pharmaceuticals and health functional foods.

Recently, it received individual recognition for the ingredient 'L. plantarum Q180,' which has the function of improving postprandial blood triglycerides, and is preparing to launch products. Based on patented technology that enhances probiotic stability and intestinal adhesion ability, it produces high-quality products.

With this agreement with Yonsei Medical Center, Chong Kun Dang Bio aims to accelerate research and development of microbiome therapeutics that reflect unmet medical needs.

A representative of Chong Kun Dang Bio said, “Recently, microbiome therapeutic development has been actively progressing domestically and internationally, focusing on metabolic diseases and neurological disorders,” adding, “Through this agreement, we will accelerate the development of 'First-in-class' and 'Best-in-class' microbiome therapeutics.”